Skip to main content
SpringerLink
Log in

Diagnosis and Drug Therapy of Prolactinoma

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

A prolactin-secreting pituitary tumour is the most frequent cause of hyperprolactinaemia that commonly occurs in clinical practice. Prolactinomas occur more frequently in women than in men and may differ in size, invasive growth and secretory activity. At presentation, macroadenomas are more frequently diagnosed in men. Specific immunohistochemical stains are necessary to prove the presence of prolactin in the tumour cells. The main investigations in the diagnosis of a prolactin-secreting adenoma are hormonal and radiological. As prolactin is a pulsatile hormone, it is a general rule to obtain several blood samples by taking a single sample on 3 separate days or 3 sequential samples (every 30 minutes) in restful conditions. Prolactin levels of 100 to 200 μg/L are commonly considered diagnostic for the presence of a prolactinoma; however, prolactinoma cannot be excluded in the presence of lower levels, and prolactin levels >100 μg/L are present in some patients with idiopathic hyperprolactinaemia.

Several dynamic function tests have been proposed to differentiate idiopathic from tumorous hyperprolactinaemia. Although they could be used for group discrimination, these tests cannot be used for individual patients. To differentiate between a prolactinoma and a pseudoprolactinoma, thyrotrophin response to a dopamine receptor antagonist may be used, as only prolactinomas may have an increased response. A short course of dopaminergic drugs may also be of some help, as in macroprolactinomas only a shrinkage may be observed. After hyperprolactinaemia is confirmed, imaging with computerised tomography (CT) and magnetic resonance imaging (MRI) are necessary to define the presence of a lesion compatible with a pituitary tumour.

There is now a general agreement that medical therapy is of first choice in patients with prolactinomas. Bromocriptine, the most common drug used in this condition, is a semisynthetic ergot alkaloid that directly stimulates specific pituitary cell membrane dopamine D2 receptors and inhibits prolactin synthesis and secretion. In most patients, a reduction or normalisation of prolactin levels is usually observed, together with the disappearance or improvement of clinical symptoms. The sensitivity to bromocriptine is variable and patients may need different doses of the drug. Bromocriptine is also able to shrink the tumour in most patients; however, a few reports of disease progression during therapy have been described. The need for close follow-up, including prolactin levels and CT or MRI studies, is therefore emphasised. Bromocriptine is conventionally given in 2 or 3 daily doses; however, a single evening dose has been shown to be equally effective. Bromocriptine is usually well tolerated by the majority of patients; some adverse effects (nausea, vomiting, postural hypotension) may be initially present, but they usually wear off in time. To prevent such adverse effects it is advisable to start treatment with a low dose during the evening meal and gradually increase the dose over days or weeks. A few patients are unable to tolerate oral bromocriptine, so different formulations of bromocriptine or alternative dopamine agonist drugs (lisuride, terguride, metergoline, dihydroergocryptine, quinagolide, cabergoline, pergolide) have been proposed. Of particular clinical relevance because of their good tolerability and sustained activity are cabergoline and quinagolide.

Particular attention should be paid to pregnancy in prolactinoma patients, as tumour enlargement has been reported. As the risk for this occurrence is low in patients with microprolactinoma, there is a general agreement that the drug can be stopped once pregnancy is diagnosed. In patients with macroprolactinoma the risk of tumour enlargement is higher. Therefore, primary therapy with bromocriptine until the tumour has shrank is suggested before pregnancy is attempted. Bromocriptine should be stopped as soon as pregnancy is confirmed, but reinstated in case of neurological complication during pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Farid NR, Buehler S, Russel NA, et al. Prolactinomas in familial multiple endocrine neoplasia syndrome type 1. Am J Med 1980 69: 874–80

    Article  PubMed  CAS  Google Scholar 

  2. Labhart A, Proesch ER, Landolt AM, et al. The adenohypophysis. In: Labhart A, editor. Clinical endocrinology: therapy and practice. Berlin: Springer Verlag, 1986; 124–6

    Chapter  Google Scholar 

  3. Schlechte J, Sherman B, Halmi N, et al. Prolactin secreting pituitary tumors in amenorrheic women: a comprehensive study. Endocr Rev 1980; 1: 295–308

    Article  PubMed  CAS  Google Scholar 

  4. Grossman A, Besser GM. Regular review: prolactinomas. BMJ 1985; 290: 182–4

    Article  PubMed  CAS  Google Scholar 

  5. Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: Degroot LY, editor. Endocrinology. Philadelphia: W.B. Saunders, 1989: 408–18

    Google Scholar 

  6. Gasser RW, Finkenstedt G, Skrabal F, et al. Multiple intracranial metastases from a prolactin secreting pituitary tumour. Clin Endocrinol 1985; 22: 17–27

    Article  CAS  Google Scholar 

  7. Davis JRE, Sheppard MC, Heath DA. Giant invasive prolactinoma: a case report and review of nine further cases. Q J Med 1990; 74: 227–38

    PubMed  CAS  Google Scholar 

  8. Asa SL, Kovacs K. Histological classification of pituitary disease. Clin Endocrinol Metab 1983; 12 (3): 567–96

    Article  PubMed  CAS  Google Scholar 

  9. Camanni F, Ciccarelli E, Ghigo E, et al. Hyperprolactinaemia: neuroendocrine and diagnostic aspects. J Endocrinol Invest 1989; 12: 653–68

    PubMed  CAS  Google Scholar 

  10. Baker HL, Berguist TH, Kispert DB, et al. Magnetic resonance imaging in a routine clinical setting. Mayo Clin Proc 1985; 60: 75–90

    PubMed  Google Scholar 

  11. Muhr C, Bergstrom K, Grimelis L, et al. A parallel study of the roentgen anatomy of the sella turcica and the pathology of the pituitary gland in 205 autopsy specimens. Neuroradiology 1981; 25: 55–65

    Article  Google Scholar 

  12. Burrow GN, Wortzman G, Rewcastle NB, et al. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 1981; 304: 156–8

    Article  PubMed  CAS  Google Scholar 

  13. Vannier MW, Marsh JL, Warren JO. Three dimensional CT reconstruction images for craniofacial surgical planning and evaluation. Radiology 1984; 150: 179–84

    PubMed  CAS  Google Scholar 

  14. Swartz YD, Russel KB, Basile BA, et al. High resolution computed tomographic appearance of the intrasellar contents in women of childbearing age. Radiology 1983; 147: 115–7

    PubMed  CAS  Google Scholar 

  15. Serri O, Rasio E, Beauregard H, et al. Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983; 309: 280–3

    Article  PubMed  CAS  Google Scholar 

  16. Rodman EF, Molitch ME, Post KD, et al. Long-term following of transsphenoidal selective adenomectomy for prolactinoma. JAMA 1984; 252: 921–4

    Article  PubMed  CAS  Google Scholar 

  17. Ciccarelli E, Ghigo E, Miola C, et al. Long term follow-up of ‘cured’ prolactinoma patients after successful adenomectomy. Clin Endocrinol (Oxford) 1990; 32: 583–92

    Article  CAS  Google Scholar 

  18. Cunnah D, Besser GM. Management of prolactinomas. Clin Endocrinol (Oxford) 1991; 34: 231–5

    Article  CAS  Google Scholar 

  19. Bevan JS, Webster J, Burke CW, et al. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13 (2): 220–40

    PubMed  CAS  Google Scholar 

  20. Wood DF, Johnston JM, Johnston DG. Dopamine, the D2 receptor and pituitary tumours. Clin Endocrinol (Oxford) 1991; 35: 455–66

    Article  CAS  Google Scholar 

  21. Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989; 69: 500–9

    Article  PubMed  CAS  Google Scholar 

  22. Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the trasforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993; 90: 7961–5

    Article  PubMed  CAS  Google Scholar 

  23. Liuzzi A, Dallabonzana D, Oppizzi G, et al. Low doses of dopamine agonist in the long-term treatment of macroprolactinomas. N Engl J Med 1985; 313: 656–60

    Article  PubMed  CAS  Google Scholar 

  24. Thorner MO, McNeilly AS, Hagan C, et al. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. BMJ 1974; ii: 419–22

    Article  Google Scholar 

  25. Nagulesparen M, Ang V and Jenkins JS. Bromocriptine treatment of males with pituitary tumours, hyperprolactinaemia, and hypogonadism. Clin Endocrin 1978; 9: 73–9

    Article  CAS  Google Scholar 

  26. Melmed S. Pituitary tumors secreting growth hormone and prolactin. Ann Int Med 1986; 105 (2): 238–53

    PubMed  CAS  Google Scholar 

  27. Barrow DL, Tindall GT, Kovacs K, et al. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumours. J Neurosurg 1984; 60: 1–7

    Article  PubMed  CAS  Google Scholar 

  28. Esiri MM, Bevan JS, Burke CW, et al. Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and non-functioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab 1986; 63: 383–8

    Article  PubMed  CAS  Google Scholar 

  29. Tindall GT, Kovacs K, Horvath E, et al. Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study. J Clin Endocrinol Metab 1982; 55: 1178–83

    Article  PubMed  CAS  Google Scholar 

  30. Landolt AM, Osterwalder V, Landolt TA. Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells. Experientia 1985; 41: 640–2

    Article  PubMed  CAS  Google Scholar 

  31. Landolt AM, Minder H, Osterwalder V, et al. Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas. Experientia 1983; 39: 625–6

    Article  PubMed  CAS  Google Scholar 

  32. Spada A, Nicosia S, Cortelazzi L, et al. In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro and microadenomas to dopamine and vasoactive intestinal peptide. J Clin Endocrinol Metab 1983; 56: 1–10

    CAS  Google Scholar 

  33. Gen M, Uozumi T, Ohta M, et al. Necrotic changes in prolactinomas after long-term administration of bromocriptine. J Clin Endocrinol Metab 1984; 59: 463–70

    Article  PubMed  CAS  Google Scholar 

  34. Breidhal HD, Topliss DJ and Pike JW. Failure of bromocriptine to mantain reduction in size of a macroprolactinoma. BMJ 1983; 287: 451–2

    Article  Google Scholar 

  35. Ciccarelli E, Mazza E, Ghigo E, et al. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinaemia. J Endocrinol Invest 1987; 10: 51–3

    PubMed  CAS  Google Scholar 

  36. Van’t Verlaat J, Lancranjan I, Hendriks MJ et al. Primary treatment of macroprolactinomas with Parlodel LAR. Acta Endocrinol 1988; 119: 51–5

    Google Scholar 

  37. Schettini G, Lombardi G, Merola B, et al. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol (Oxford) 1990; 33: 161–9

    Article  CAS  Google Scholar 

  38. Ciccarelli E, Miola C, Grottoli S, et al. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine. J Clin Endocrinol Metab 1993; 76: 484–8

    Article  PubMed  CAS  Google Scholar 

  39. Ciccarelli E, Grottoli S, Miola C, et al. Double blind randomized study using oral or injectable bromocriptine in patients with hyperprolactinaemia. Clin Endocrinol 1994; 40: 193–8

    Article  CAS  Google Scholar 

  40. Kletzky OA, Vermesh M. Effectiveness of vaginal bromocriptine in treating women with hyperprolactinaemia. Fertil Steril 1989; 51: 269–72

    PubMed  CAS  Google Scholar 

  41. Rasmussen C, Bergh T, Wide L, et al. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205–502, in women with hyperprolactinemia. Clin Endocrinol (Oxford) 1988; 29: 271–9

    Article  CAS  Google Scholar 

  42. Vance ML, Cragun JR, Reimnitz C, et al. CV 205–502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 1989; 68: 336–9

    Article  PubMed  CAS  Google Scholar 

  43. Khalfallah Y, Claustrat B, Grochowicki M, et al. Effect of a new prolactin inhibitor, CV 205–502 in the treatment of human macroprolactinomas. J Clin Endocrinol Metab 1990; 71: 354–9

    Article  PubMed  CAS  Google Scholar 

  44. Brue T, Pellegrini I, Gunz G, et al. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992; 74: 577–84

    Article  PubMed  CAS  Google Scholar 

  45. Franks S, Horrocks PM, Lynch SS, et al. Effectiveness of pergolide mesylate in long-term treatment of hyperprolactinaemia. BMJ 1983; 286: 1177–9

    Article  PubMed  CAS  Google Scholar 

  46. Kleinberg DL, Boyd AE, Wardlaw S, et al. Pergolide for the treatment of pituitary tumours secreting prolactin or growth hormone. N Engl J Med 1983; 309: 704–9

    Article  PubMed  CAS  Google Scholar 

  47. Rains C, Bryson H, Fitton A. Cabergoline: a review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactiation. Drugs 1995 Feb; 49 (2): 255–79

    Article  PubMed  CAS  Google Scholar 

  48. Pontiroli AE, Cammeli L, Baroldi P, et al. Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long acting dopaminergic drug. J Clin Endocrinol Metab 1987; 65: 1057–9

    Article  PubMed  CAS  Google Scholar 

  49. Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactinlowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941–5

    Article  PubMed  CAS  Google Scholar 

  50. Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989; 69: 725–8

    Article  PubMed  CAS  Google Scholar 

  51. Page S and Nussey S. Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient. J Obstet Gynaecol 1989; 10: 156–7

    Article  Google Scholar 

  52. Webster J, Piscitelli G, Polli A, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994; 331: 904–9

    Article  PubMed  CAS  Google Scholar 

  53. Ferrari C, Paracchi A, Mattei AM, et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992; 126: 489–94

    PubMed  CAS  Google Scholar 

  54. Magyar DM, Marshall JR. Pituitary tumours and pregnancy. Am J Obstet Gynecol 1978; 132: 739–49

    PubMed  CAS  Google Scholar 

  55. Lamberts SWJ, Klijn JGM, de Lange SA, et al. The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with radiologically evident pituitary tumors. Fertil Steril 1979; 31: 614–9

    PubMed  CAS  Google Scholar 

  56. Crosignani PG, Ferrari C, Scarduelli C, et al. Spontaneous and induced pregnancies in hyperprolactinaemic women. Obstet Gynecol 1981; 58 (6): 708–13

    PubMed  CAS  Google Scholar 

  57. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985; 23: 1364–70

    Article  Google Scholar 

  58. Gemzeil C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979; 31 (4): 363–72

    Google Scholar 

  59. Canales E, Garcia I, Ruiz J, et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril 1981; 35 (4): 524–6

    Google Scholar 

  60. De Wit W, Coelingh Bennik HJT, Gerards LJ. Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas: report of 13 pregnancies. Br J Obstet Gynaecol 1984; 91: 1059–69

    Article  PubMed  Google Scholar 

  61. Van Roon E, Van Der Vijver JCM, Gerretsen G, et al. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil Steril 1981; 36: 173–7

    PubMed  Google Scholar 

  62. Falsetti L, Zanagnolo V, Galbignani E. Cabergoline treatment in hyperprolactinemic women. J Obstet Gynecol 1991; 11: 68–71

    Article  Google Scholar 

  63. Tamburrano G, Jafrain-Rea ML, Bulletta C, et al. Cabergoline and bromocriptine-induced pregnancies in women with non operated microprolactinomas [abstract]. J Endocrinol Invest 1991; 14 (1): 104

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna, Università di Torino, Ospedale Molinette, Corso Dogliotti 14, 10126, Torino, Italy

    Enrica Ciccarelli & Franco Camanni

Authors
  1. Enrica Ciccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franco Camanni
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciccarelli, E., Camanni, F. Diagnosis and Drug Therapy of Prolactinoma. Drugs 51, 954–965 (1996). https://doi.org/10.2165/00003495-199651060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651060-00004

Keywords

Search

Navigation